Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic and erosive polyarthritis causing irreversible joint disability. It is the most common persistent inflammatory arthritis, affecting from 0.5 to 1% of the general population worldwide. Antibodies to citrullinated proteins (anti-CCP antibody) have been described in patients with RA and these appear to be the most specific marker of the disease. Methods: This cross-sectional study was carried out at department of medicine, Sher-E-Bangla Medical College Hospital, Barisal Form July’ 2016 to December’ 2016. All rheumatoid arthritis patients attending at OPD and those got admitted under Medicine Dept, who was satisfying the inclusion and exclusion criteria were included consecutively and purposively in this study. Results: Total 70 cases were included; the mean age was found 46.57±13.10 years in anti-CCP antibody positive group and 44.19±11.21 years in anti-CCP antibody negative group. Female were predominant in both groups. Duration of disease was around 8 years in both groups. Mean ESR was 29.0±22.0 mm in anti-CCP antibody positive group and 12.25±10.6 mm in anti-CCP antibody negative group. Mean rheumatoid factor was 189.4±102.1 U/L in anti-CCP antibody positive group and 66.5±36.0 U/L in anti-CCP antibody negative group. Mean DAS 28 score was 4.6±1.4 and 3.6±1.3 in anti-CCP antibody positive and negative group respectively. The mean difference was statistically significant (p<0.05) between the groups. Patients in disease remission had lower anti-CCP antibody titer than those with low, moderate or high disease activity. Significantly positive correlation (r=0.596; p=0.001) between severity of rheumatoid arthritis and anti CCP antibody level was observed. Conclusion: In RA patients’ disease was more severe in anti-CCP antibody positive group and significantly positive correlation between anti-CCP antibody level with disease severity of RA was observed. BIRDEM Med J 2022; 12(1): 36-40

No abstract

Impaired lipid metabolism in diabetic patients can lead to cardiovascular complications. Poor glycaemic control is associated with a significant increase in the risk of both patient’s morbidity and mortality. An early intervention to regulate circulating lipids has been found to lower the risk of cardiovascular problems and death. Glycated hemoglobin (HbA1c) is a reliable indicator of rising blood sugar levels. This hospital based observational study was conducted in the Department of Medicine, Sher-E-Bangla Medical College Hospital, Barisal from October 2014 to March 2015 over a period of 6 month to determine the correlation of glycemic control and lipid profile in patients with type 2 diabetes. A total of 110 type 2 diabe- tes mellitus(DM) patients of both sexes admitted to the Deapartment of Medicine of Sher-E- Bangla Medical College Hospital, Barisal, were recruited for this study. Following standard procedures and protocols, fasting blood sugar (FBS), blood sugar two hours after breakfast, Glycosylated Hemoglobin (HbA1c) and fasting lipid profile were measured. The age of respondents ranged from 34 to 70 years with the mean age of 54.35}8.02 years. Among the patients male were 70 (63.6%) and female were 40 (36.4%). Mean age at diagnosis of DM and duration of DM was 47.07}6.03 years and 7.27}3.41 years, respectively. Mean body mass index (BMI), FBS and HbA1c were 25.02}5.22 kg/m2, 8.06}2.01 mmol/L and 8.34}1.9 % respectively. Significant positive correlation of HbA1c and FBS with BMI, total cholester- ol(TC), triglyceride(TG), low density lipoprotein(LDL-C) and negative correlation with high density lipoprotein (HDL-C) was found. Significantly higher TC, TG and LDL-C and lower HDL-C were found in poor glycemic control (HbA1c ≥ 7) group than good glycemic control (HbA1c < 7 ) group. The results of this study showed that , higher levels of glycemic parame- ters are significantly associated with dyslipidemia. These findings also indicate that HbA1c can be utilized for screening of high risk diabetic patients for early diagnosis of dyslipidemia and timely intervention with lipid lowering drugs. BSMMU J 2021; 14(4): 138-143

No abstract

No abstract

No abstract

No abstract

No abstract